The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review.

Sachin M. Shridharani, Michael Magarakis, Paul Manson, Navin K Singh, Basak Basdag, Gedge David Rosson

Research output: Contribution to journalArticle

Abstract

The management of keloids and hypertrophic scars continues to challenge health-care providers. Though both forms of pathologic scarring are distinct entities at the macro and microscopic level, their etiologies and treatment are often similar. Potential treatment approaches are progressing, and combinations of treatment options have been proposed in the literature with promising outcomes. The treatment evolution has reached a level where molecular therapeutic modalities are being investigated. Currently, no gold standard treatment exists. Overall success rates and patient satisfaction seem to be slowly climbing, but additional investigational studies must continue to be performed. Several studies have investigated antineoplastic agents, and there seems to be a marked improvement in rates of recurrence, patient satisfaction, and overall quality of scar when these agents are used. Intralesional injection and/or wound irrigation with interferon-a2b, interferon-g, mitomycin-C, bleomycin, or 5-fluorouracil seems to have a positive effect on the reduction of pathologic scars. There is mounting evidence that these drugs used alone or in combination therapy, have the potential to be an integral part of the treatment paradigm for hypertrophic scars and keloids.

Original languageEnglish (US)
Pages (from-to)355-361
Number of pages7
JournalAnnals of Plastic Surgery
Volume64
Issue number3
Publication statusPublished - Mar 2010

    Fingerprint

ASJC Scopus subject areas

  • Surgery

Cite this